Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the 14 best booming stocks to buy right now. The stock is surging and has gained over 57% in the last three months, as of the close on January 12. Shares closed 3% higher on Tuesday, January 13, after the company provided a corporate update and outlined its priorities for 2026. Major milestones for the current year include the expectation of top-line findings for Sevasemten by the fourth quarter, which would be the first approved therapy for patients with Becker disease. On the other hand, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is also anticipating Phase 2 results for its selective cardiac sarcomere modulator, EDG-7500, during the first half of the year, to treat hypertrophic cardiomyopathy (HCM). The stock has a one-year average share price target of $38.14, representing an upside potential of 58.06%, as of January 12. Wall Street analysts remain bullish on Edgewise with a consensus Strong Buy rating. Recently, it has been on the radar of several research firms. On December 24, Stifel Nicolaus maintained a Hold rating on the stock with a $16 price target. On the same day, JPMorgan analyst Tessa Romero also reiterated the firm’s Overweight rating on the stock. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company developing therapeutics for muscular dystrophies and cardiac diseases. While we acknowledge the potential of EWTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026 Disclosure: None.